BenzingaSeptember 22, 2026 at 5:22 AM NYLast Month
Lunai Bioworks Enters Exclusive Worldwide License And Collaboration Agreement With Tanaist To Add Human Cellular Phenotyping To Its Parkinson's Disease Discovery And Validation Platform
The collaboration is designed to connect patient subtypes identified by BioSymetrics, Lunai's wholly owned subsidiary, using its Augusta AI platform with independent patient cohorts and measurable human cellular
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
